A Study of LY3209590 in Participants With Type 2 Diabetes

Summary

This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects will be documented. This study will last approximately 17 weeks, not including screening. Screening is required within 4 weeks prior to the start of the study.

Timeline

Start

2018-01-03

Primary completion

2018-10-03

Completion

2018-10-03

Drugs

Indications